Signaturefd, LLC Vir Biotechnology, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 585 shares of VIR stock, worth $5,838. This represents 0.0% of its overall portfolio holdings.

Number of Shares

585

Previous 3,124 81.27%

Holding current value

$5,838

Previous $27,000 85.19%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	SELL	$7.26 - $10.7 $18,433 - $27,167	-2,539 Reduced 81.27%	585 $4,000
Q2 2024 Jul 29, 2024	BUY	$7.63 - $12.66 $183 - $303	24 Added 0.77%	3,124 $27,000
Q1 2024 May 03, 2024	SELL	$8.6 - $11.9 $1,952 - $2,701	-227 Reduced 6.82%	3,100 $31,000
Q4 2023 Jan 31, 2024	BUY	$7.76 - $10.29 $18,616 - $24,685	2,399 Added 258.51%	3,327 $33,000
Q3 2023 Nov 03, 2023	BUY	$9.14 - $24.62 $7,942 - $21,394	869 Added 1472.88%	928 $8,000
Q2 2023 Aug 01, 2023	SELL	$23.2 - $27.29 $28,791 - $33,866	-1,241 Reduced 95.46%	59 $1,000
Q1 2023 Apr 28, 2023	BUY	$22.26 - $30.85 $26,890 - $37,266	1,208 Added 1313.04%	1,300 $30,000
Q4 2022 Jan 27, 2023	SELL	$19.96 - $28.22 $1,477 - $2,088	-74 Reduced 44.58%	92 $2,000
Q3 2022 Nov 08, 2022	BUY	$18.26 - $31.1 $146 - $248	8 Added 5.06%	166 $3,000
Q2 2022 Aug 10, 2022	BUY	$19.08 - $26.7 $1,411 - $1,975	74 Added 88.1%	158 $4,000
Q1 2022 May 02, 2022	SELL	$21.19 - $40.01 $1,928 - $3,640	-91 Reduced 52.0%	84 $2,000
Q4 2021 Jan 25, 2022	BUY	$30.97 - $54.03 $1,920 - $3,349	62 Added 54.87%	175 $7,000
Q3 2021 Oct 28, 2021	BUY	$34.9 - $54.54 $907 - $1,418	26 Added 29.89%	113 $5,000
Q2 2021 Jul 26, 2021	BUY	$38.75 - $51.0 $3,371 - $4,437	87 New	87 $4,000

Others Institutions Holding VIR

# of Institutions

215

Shares Held

85.2M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.32B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account